![John Aston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Aston
Net worth: 79 702 $ as of 31/05/2024
Network origin in John Aston first degree
Entity | Entity type | Industry | |
---|---|---|---|
Mutual Fd-Closed End | Investment Trusts/Mutual Funds | 13 | |
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.
13
| Subsidiary | Biotechnology | 13 |
Mutual Fd-Closed End | Investment Trusts/Mutual Funds | 5 | |
Astex Therapeutics Ltd.
![]() Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom.
2
| Extinct | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to John Aston via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Janus Henderson Investors UK Ltd.
![]() Janus Henderson Investors UK Ltd. Investment ManagersFinance Janus Henderson Investors UK Ltd. (JHI UK) is the wholly-owned global asset management subsidiary of Janus Henderson UK (Holdings) Ltd., ultimately held by Janus Henderson Group Plc (LON: 0RPW; NYSE: JHG) in Great Britain. The firm was founded in 1934 and formerly known as Henderson Global Investors Ltd. Headquartered in London, JHI UK is a client-centric, sustainable and responsible investor which provides investment management services to individuals, private banks, third party distributors, insurance companies, pension funds, government bodies, investment trusts, charities and corporate entities. | Investment Managers | Director/Board Member Portfolio Manager-Equities | |
SV Health Investors LLP
![]() SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Director of Finance/CFO Private Equity Investor | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Janssen-Cilag Ltd.
![]() Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Phoqus Pharmaceuticals Plc
![]() Phoqus Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK. | Pharmaceuticals: Major | Chief Executive Officer | |
The Association of Investment Cos.
![]() The Association of Investment Cos. Investment Trusts/Mutual FundsMiscellaneous The Association of Investment Cos. is based in London, UK. The British company represents and provides investor data on closed-ended funds, including investment trusts and venture capital trusts (VCTs). The non-profit company was founded in 1932. Richard William Stone has been the CEO of the company since 2021. | Investment Trusts/Mutual Funds | Chairman Chairman | |
WITAN INVESTMENT TRUST PLC | Investment Trusts/Mutual Funds | Chief Investment Officer Chief Executive Officer | |
BTG | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
University of Oxford | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Graduate Degree | |
University of Glasgow | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
Xention Pharma Ltd.
![]() Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Masters Business Admin | |
Dobbies Garden Centres Ltd.
![]() Dobbies Garden Centres Ltd. Wholesale DistributorsDistribution Services Dobbies Garden Centres Ltd. engages in the provision of equipment, products, and consumables for the horticulture industry. Its products include bedding plants, bulbs and seeds, houseplants, shrubs, roses, bird care, garden clothing and accessories, garden machinery and tools, pots, planters and hanging baskets, outdoor heating, garden decor and water features, and outdoor lighting. The company was founded by James Dobbie in 1865 and is headquartered in Lasswade, the United kingdom. | Wholesale Distributors | Chairman | |
University of Leeds | College/University | Masters Business Admin | |
University of London | College/University | Doctorate Degree Undergraduate Degree | |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ApaTech Ltd.
![]() ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Medical Specialties | Chairman Human Resources Officer | |
University of Durham | College/University | Undergraduate Degree Undergraduate Degree | |
The University of Nottingham | College/University | Undergraduate Degree | |
University College London | College/University | Undergraduate Degree Undergraduate Degree | |
7TM A/S
![]() 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Chairman Chairman | |
NM Rothschild & Sons (Hong Kong) Ltd.
![]() NM Rothschild & Sons (Hong Kong) Ltd. Investment Banks/BrokersFinance Part of Rothschild Concordia SAS, NM Rothschild & Sons (Hong Kong) Ltd. is a Chinese company that provides merchant, investment, private banking and stock broking services. The company is based in Hong Kong, Hong Kong. | Investment Banks/Brokers | Corporate Officer/Principal | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Faculty of Pharmaceutical Medicine | Director/Board Member Corporate Officer/Principal | ||
Celltech R&D, Inc.
![]() Celltech R&D, Inc. Drugstore ChainsRetail Trade Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA. | Drugstore Chains | Corporate Officer/Principal | |
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
Jordan/Zalaznick & Co. Ltd. | Director/Board Member | ||
MIGO OPPORTUNITIES TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member | |
Astex Pharmaceuticals, Inc.
![]() Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Xention Ltd.
![]() Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member | |
TopiVert Ltd.
![]() TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
PCGH ZDP Plc
![]() PCGH ZDP Plc Investment Trusts/Mutual FundsMiscellaneous PCGH ZDP Plc is a closed-end investment fund. It generates capital growth by investing in a global portfolio of healthcare stocks across all healthcare sectors. The company was founded March 30, 2017 and was headquartered in London, the United Kingdom. | Investment Trusts/Mutual Funds | Director/Board Member Chairman Chairman Director/Board Member | |
Apollo Therapeutics LLP
![]() Apollo Therapeutics LLP Financial ConglomeratesFinance Apollo Therapeutics LLP is a British biopharmaceutical company that focuses on translating medical research into medicines. The company is based in Stevenage, UK. The company has a portfolio-model built around a centralized management team of experts in pharmaceutical R&D, manufacturing, commercial strategy, fundraising, and business development. The company's assets are housed in separate wholly-owned subsidiary companies, which incorporate best practices from big pharma and venture capital. The company has a scalable R&D platform for the discovery and development of new medicines, enabled by access to five of the world's leading universities and research institutes. The company was founded in 2015, and the CEO is Richard Mason. | Financial Conglomerates | Chief Executive Officer | |
Apollo Therapeutics Group Ltd.
![]() Apollo Therapeutics Group Ltd. Financial ConglomeratesFinance Apollo Therapeutics Group Ltd. is an investment holding British company. The private company is based in Cambridge, UK. The company was founded in 2021. The CEO is Richard Mason. | Financial Conglomerates | Chief Executive Officer | |
NewAmsterdam Pharma BV
![]() NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Statistics
International
United Kingdom | 36 |
United States | 5 |
Denmark | 4 |
Switzerland | 4 |
Netherlands | 3 |
Sectoral
Health Technology | 24 |
Consumer Services | 10 |
Finance | 9 |
Miscellaneous | 6 |
Distribution Services | 2 |
Operational
Director/Board Member | 167 |
Corporate Officer/Principal | 72 |
Chairman | 66 |
Independent Dir/Board Member | 63 |
Chief Executive Officer | 20 |
Most connected contacts
Insiders | |
---|---|
Ismail Kola | 26 |
Peter Chambré | 23 |
David Chiswell | 23 |
Peter S. Ringrose | 19 |
Carl Harald Janson | 19 |
Lisa Arnold | 16 |
Tony Brampton | 16 |
Alan Henry Clifton | 16 |
Caroline Gulliver | 15 |
James Robinson | 15 |
Hamish Alan Cameron | 14 |
Robert Alexander Hammond-Chambers | 14 |
John Wilcox Stocker | 12 |
Martin Buckland | 12 |
Patrick John Magee | 12 |
- Stock Market
- Insiders
- John Aston
- Company connections